The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1609
October 19, 2020
View Complete Issue         Table of Contents 2019 
Issue 1609
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Timing of Remdesivir for COVID-19
October 19, 2020 (Issue: 1609)
Remdesivir (Veklury – Gilead), an investigational antiviral drug administered by IV infusion, is now available through an FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in all hospitalized patients. An earlier EUA limited use...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1609
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.